← Leaderboards
Guan Chen
Loyola University Chicago
$3,958,822
Attributed
$3,958,822
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $356.9K · FY2006–25$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,958,822 · 2
VA$0 · 3
By mechanism
R01$3,958,822 · 2
I01$0 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Phosphorylation”
- Paul S. Aisen · Cognition Therapeutics, Inc.$88,828,963
- Alan F Horwitz · University Of Virginia Charlottesville$38,916,638
- Tony R. Hunter · Salk Institute For Biological Studies$34,955,666
- Adam L Boxer · Mayo Clinic Rochester$31,930,809
- Keith A. Johnson · Banner Health$30,350,302
- Paul Greengard · Rockefeller University$28,632,392
Research focus
PhosphorylationGrowthSignal TransductionSpecimenPathway InteractionsComplexTherapeutic InterventionMalignant - DescriptorIn VitroPhosphotransferasesIn VivoMalignant NeoplasmsKnock-OutProteinsMapk12 GeneTissuesColon CarcinomaResponsePirfenidoneCancer CellMap Kinase GenePlayInhibitor/AntagonistTargeted Treatment
Grant awards (29)
p38gamma MAPK signaling promotes intestinal tumorigenesis$239,536
R01 · FY2025 · CA · contact PI
p38gamma MAPK signaling promotes intestinal tumorigenesis$99,472
R01 · FY2024 · CA · contact PI
Glycolytic signaling of p38gamma in breast cancer$0
I01 · FY2024 · VA · contact PI
p38gamma MAPK signaling promotes intestinal tumorigenesis$349,713
R01 · FY2023 · CA · contact PI
Glycolytic signaling of p38gamma in breast cancer$0
I01 · FY2023 · VA · contact PI
p38gamma MAPK signaling promotes intestinal tumorigenesis$349,713
R01 · FY2022 · CA · contact PI
Glycolytic signaling of p38gamma in breast cancer$0
I01 · FY2022 · VA · contact PI
p38gamma MAPK signaling promotes intestinal tumorigenesis$356,850
R01 · FY2021 · CA · contact PI
Glycolytic signaling of p38gamma in breast cancer$0
I01 · FY2021 · VA · contact PI
p38gamma MAPK signaling promotes intestinal tumorigenesis$356,469
R01 · FY2020 · CA · contact PI
A protein-complex as a novel therapeutic target for K-Ras dependent colon cancer$0
I01 · FY2018 · VA · contact PI
A protein-complex as a novel therapeutic target for K-Ras dependent colon cancer$0
I01 · FY2017 · VA · contact PI
A protein-complex as a novel therapeutic target for K-Ras dependent colon cancer$0
I01 · FY2016 · VA · contact PI
A protein-complex as a novel therapeutic target for K-Ras dependent colon cancer$0
I01 · FY2015 · VA · contact PI
Estrogen receptor, p38 MAPKs and topo IIa in breast cancer$0
I01 · FY2013 · VA · contact PI
Estrogen receptor, p38 MAPKs and topo IIa in breast cancer$0
I01 · FY2012 · VA · contact PI
Estrogen receptor, p38 MAPKs and topo IIa in breast cancer$0
I01 · FY2011 · VA · contact PI
Regulation of Ras activity by the p38 pathway$223,970
R01 · FY2010 · CA · contact PI
Regulation of Ras activity by the p38 pathway$223,970
R01 · FY2009 · CA · contact PI
Estrogen receptor, p38 MAPKs and topo IIa in breast cancer$0
I01 · FY2009 · VA · contact PI
Regulation of Ras activity by the p38 pathway$223,970
R01 · FY2008 · CA · contact PI
Regulation of Ras activity by the p38 pathway$223,970
R01 · FY2007 · CA · contact PI
Regulation of Ras activity by the p38 pathway$174,882
R01 · FY2006 · CA · contact PI
Regulation of Ras activity by the p38 pathway$55,777
R01 · FY2006 · CA · contact PI
Inhibition of Ras mitogenic signaling by the 38 pathway$216,600
R01 · FY2004 · CA
Inhibition of Ras mitogenic signaling by the 38 pathway$216,600
R01 · FY2003 · CA
Inhibition of Ras mitogenic signaling by the 38 pathway$216,600
R01 · FY2002 · CA
Inhibition of Ras mitogenic signaling by the 38 pathway$216,600
R01 · FY2001 · CA
Inhibition of Ras mitogenic signaling by the P38 pathway$214,130
R01 · FY2000 · CA